BEUDAMED
    FDA Adverse Event Injury Summary report: N

    BAERVELDT GLAUCOMA IMPLANT (350)

    MDR report key: 11971008 · Received June 9, 2021

    Report

    Report Number
    9614546-2021-07206
    Event Type
    Injury
    Date Received
    June 9, 2021
    Report Date
    June 9, 2021
    Manufacturer
    AMO MANUFACTURING NETHERLANDS
    Product Code
    KYF
    UDI-DI
    05050474512993
    PMA / PMN Number
    K905129
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    PE
    Reporter Occupation
    PHYSICIAN

    Narratives

    Additional Manufacturer Narrative · 1

    AGE/DATE OF BIRTH: MEAN AGE WAS (B)(6). SEX/GENDER: A TOTAL OF 16 FEMALES, 26 MALES. INFORMATION UNKNOWN/NOT PROVIDED. DATE OF EVENT: (B)(6) 2021 (THE DATE ARTICLE WAS PUBLISHED). IF IMPLANTED; GIVE DATE: UNKNOWN/NOT PROVIDED. IF EXPLANTED; GIVE DATE: UNKNOWN/NOT PROVIDED. TELEPHONE NUMBER: (B)(6).. IT WAS INDICATED THAT THE DEVICE IS NOT RETURNING FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE CANNOT BE COMPLETED. A REVIEW OF THE DEVICE HISTORY RECORD, COMPLAINT TRENDING, AND RISK DOCUMENTATION FOR THIS DEVICE WILL BE PERFORMED. UPON COMPLETION OF THE REVIEW, IF THERE IS ANY FURTHER RELEVANT INFORMATION A SUPPLEMENTAL MEDWATCH WILL BE FILED. (B)(6), (2021). PRIMARY OUTCOMES OF BAERVELDT GLAUCOMA IMPLANTS WITH A MODIFIED TECHNIQUE TO CONTROL INTRAOCULAR PRESSURE IN DIFFERENT CASES OF GLAUCOMA. INTERNATIONAL OPHTHALMOLOGY 55(1), (B)(6). ALL PERTINENT INFORMATION AVAILABLE TO JOHNSON & JOHNSON SURGICAL VISION, INC. HAS BEEN SUBMITTED.

    Description of Event or Problem · 1

    THE FOLLOWING ARTICLE WAS RECEIVED BASED ON A LITERATURE REVIEW: ARTICLE: PRIMARY OUTCOMES OF BAERVELDT GLAUCOMA IMPLANTS WITH A MODIFIED TECHNIQUE TO CONTROL INTRAOCULAR PRESSURE IN DIFFERENT CASES OF GLAUCOMA. A RETROSPECTIVE COHORT STUDY WAS DONE TO DESCRIBE THE OUTCOMES OF BAERVELDT GLAUCOMA IMPLANTS (BGI; ABBOTT MEDICAL OPTICS) IMPLANTED VIA A MODIFIED TECHNIQUE WITH REGARD TO EARLY INTRAOCULAR PRESSURE (IOP) REDUCTION IN CASES OF UNCONTROLLED GLAUCOMA. A TOTAL OF 42 EYES OF 42 PATIENTS WITH GLAUCOMA UNDERWENT BGI IMPLANTATION WITH THE MODIFIED TECHNIQUE WITH OCCLUSION AND FENESTRATIONS OF THE TUBE. THIRTY-SEVEN (37) EYES WERE IMPLANTED WITH BGI 350 MM2 MODEL AND 5 EYES WERE IMPLANTED WITH BGI 250 MM2 MODEL. DURING THE PROCEDURE, A VICRYL 8.0 TRACTION TO THE SUPERIOR PERIPHERAL CORNEA AT 50% THICKNESS WAS PERFORMED THEN AFTER PARACENTESIS WITH A 15-DEGREE KNIFE, A VISCOELASTIC HEALON GV OVD (ABBOTT MEDICAL OPTICS INC.) WAS INJECTED INTO THE ANTERIOR CHAMBER. LASTLY, THREE DOUBLE PERFORATED CUTS WERE MADE IN THE TUBE WITH A SPATULATED NEEDLE, AND FENESTRATIONS WERE MADE WITH A VICRYL 7¿0 SUTURE, 1¿3 MM POSTERIOR TO THE SCLERAL NEEDLE TRACK THEN THE CONJUNCTIVA WAS FINALLY SUTURED WITH VICRYL 7¿0. ONE MONTH AFTER SURGERY, 3 EYES HAD TUBE OCCLUSION AND ALL SUCCESSFULLY UNDERWENT LASER TREATMENT; 1 EYE HAD FOCAL CHOROIDAL HEMORRHAGE WHICH WAS CONFIRMED BY AN ULTRASOUND SCAN AND RESOLVED SPONTANEOUSLY WITH MEDICAL TREATMENT; 1 EYE EXPERIENCED ANTERIOR DISPLACEMENT OF THE TUBE WHICH NEEDED TO BE CUT THROUGH BY A CLEAR CORNEAL INCISION; AND 1 EYE EXPERIENCED CORNEAL DECOMPENSATION THAT NEEDED DESCEMET MEMBRANE ENDOTHELIAL KERATOPLASTY (DMEK). IT IS NOT CLEAR WHICH DEVICE THE COMPLICATIONS ARE RELATED TO. THROUGH FOLLOW-UP, IT WAS LEARNED THAT THE PATIENT HAD CORNEAL DECOMPENSATION IN THE RIGHT EYE AND WAS TREATED WITH DMEK. THE DEVICE IS NOT AVAILABLE FOR RETURN. NO FURTHER INFORMATION WAS AVAILABLE. THIS REPORT CAPTURES THE EVENT FOR BAERVELDT SHUNT 350 #3 OF THE 3 REPORTED EVENTS. A SEPARATE REPORT IS BEING SUBMITTED FOR EACH OF THE 3 BAERVELDT SHUNT 350.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    863562 BAERVELDT GLAUCOMA IMPLANT (350) IMPLANT, EYE VALVE KYF AMO MANUFACTURING NETHERLANDS BG101350 05050474512993

    Patients

    Seq Age Sex Outcome Treatment
    1 Required Intervention